,16 For neoadjuvant therapy with ICIs in breast cancer, PD-L1 expression by IHC did not predict selective benefit from inclusion of ICIs with chemotherapy in either the KEYNOTE-522 or the NeoTRIPaPDL1 trials.5 This evidence concerns the gene CD274 and breast cancer.